On November 16, 2021 Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapies in oncology, reported the presentation of preclinical data on the company’s new anti-CD27 agonist monoclonal antibody program at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 36th Anniversary Annual Meeting, that took place November 10-14, 2021 in Washington D.C (Press release, Kineta, NOV 16, 2021, View Source;utm_medium=rss&utm_campaign=kineta-presented-compelling-preclinical-data-on-its-new-cd27-antibody-program-at-the-2021-sitc-annual-meeting [SID1234595690]). Thierry Guillaudeux, PhD, Senior Vice President Immuno-oncology at Kineta, presented a poster revealing new binding affinity and specificity data on the company’s CD27 monoclonal antibody drug candidates as well as potent agonistic activity on cellular and T cell activation assays.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are highly encouraged with the compelling preclinical data demonstrated with Kineta’s new CD27 monoclonal antibodies" said Thierry Guillaudeux, PhD, Senior Vice President Immuno-oncology at Kineta. "CD27 is a promising cancer immunotherapy approach that can mobilize new specific tumor antigen specific T cells to drive a potent anti-tumor response with single agent efficacy as well as synergistic effects with other immune checkpoint inhibitors.

Kineta has developed a diverse set of anti-CD27 agonist antibodies. They are fully human monoclonal antibodies (mAbs) that demonstrate low nanomolar (nM) binding affinity to CD27 in humans. In preclinical studies, Kineta’s selected lead anti-CD27 agonist mAbs induce T cell proliferation and secretion of cytokines involved in T cell priming and recruitment, demonstrating the ability to potentiate new anti-tumor responses. Kineta is in the final stage of lead selection and plans to nominate a clinical candidate in Q1-Q2 2022.

Key results from the SITC (Free SITC Whitepaper) poster presentation:

147 fully human anti-CD27 monoclonal antibodies with unique sequences were generated
Anti-CD27 agonist assay showed strong agonist activity for 8 pre-selected anti-CD27 antibodies
Human T cell activation assay data for 5 mAbs showed increased proliferation and cytokine secretion
Further in vitro and in vivo developments are on-going to select our lead anti-CD27 agonist antibody
Presentation Details:

Title: A promising cancer immunotherapy target: Novel agonistic human antibodies against the human T-cell costimulatory receptor CD27
Date Presented: November 12-13, 2021
Presenter: Thierry Guillaudeux, PhD
Poster: Click on the link below to view the poster:

CD27 Publications – Poster Presentation at SITC (Free SITC Whitepaper) 2021

On November 16, 2021 Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, reported that its President and Chief Executive Officer, Rodney Varner, will be presenting in November with CEO Roadshow to provide a company overview of its novel gene therapies in cancer and diabetes to investors (Press release, Genprex, NOV 16, 2021, View Source [SID1234595689]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details for the November CEO Roadshow webinar:

Host: CEO Roadshow

Date and Time: Wednesday, Nov. 17 at 11 a.m. ET

Webinar Link: https://bit.ly/3bCwvPU

Mr. Varner will be available for questions following the company presentation. The webinar will be recorded and available for replay on Genprex’s website for a period of time. A replay will also be available on CEORoadshow.com following the webinar.

The CEO Roadshow webinar series features small and mid-cap stocks that are on the verge of a breakout or have other near-term developments making them an attractive long-term investment opportunity.

On November 15, Xenetic Biosciences, Inc. (the "Company") reported that entered into a letter agreement (the "Agreement") with the holders (the "Holders") of the Company’s common stock purchase warrants (the "Warrants") issued pursuant to that certain Securities Purchase Agreement, dated March 5, 2019, by and among the Company and the purchasers party thereto (the "Purchase Agreement") (Filing, 8-K, Xenetic Biosciences, NOV 16, 2021, View Source [SID1234595688]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Pursuant to the Agreement, the Purchase Agreement was amended to delete, in its entirety, Section 4.12(b) of the Purchase Agreement. Additionally, the Company and the Holders agreed to exchange the Warrants to purchase 129,084 shares of the Company’s common stock, par value $0.001 per share ("Common Stock"), for an aggregate of 51,634 shares of Common Stock (the "Exchange"). Other than the foregoing, neither party provided cash or other securities as consideration in the Exchange. As a result of the Exchange, all of the Holder’s Warrants were cancelled without further action required by either the Company or the Holders. The Agreement contains customary representations and warranties by the Company and the Holders.

On November 16, 2021 AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, reported that chairman and CEO Dr. Hans S. Keirstead will deliver a keynote at the Vaccine World Asia Congress (Press release, AIVITA Biomedical, NOV 16, 2021, View Source [SID1234595687]). The Singapore-based congress is being held virtually November 17-18. Dr. Keirstead’s speaking details are as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Keynote: A Fully Personalized COVID-19 Vaccine Made at Point-of-Care
When: Wednesday, November 17, 4:00 PM (GMT +8)
Location: Virtual – Singapore

In his keynote, Dr. Keirstead will share findings from AIVITA’s ongoing trials in COVID-19 and discuss the advantages of a personalized vaccine made at point-of-care.

On November 16, 2021 VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, reported that Jeff Baxter, President and CEO, will participate in an analyst-led fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 17 at 12:20 PM GMT / 7:20 AM ET (Press release, VBI Vaccines, NOV 16, 2021, View Source [SID1234595686]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jefferies London Healthcare Conference

Discussion to be held with Kelechi Chikere, Ph.D.

Presenter: Jeff Baxter, President and CEO
Date: Wednesday, November 17, 2021
Time: 12:20-12:55 PM GMT / 7:20-7:55 AM ET
Webcast Link: View Source
Live webcasts of the presentations will also be available on the Investors page of VBI’s website at: View Source A replay of each webcast will be archived on the Company’s website following the presentation.